Literature DB >> 1676265

Bispecific antibodies and targeted cellular cytotoxicity.

M W Fanger1, D M Segal, J L Romet-Lemonne.   

Abstract

The Second International Conference on Bispecific Antibodies (BsAbs) and Targeted Cellular Cytotoxicity considered how targeted cytotoxicity can be used (1) to increase understanding of the general mechanisms of cellular cytotoxicity and (2) clinically in the treatment of cancer and infectious disease. BsAbs, the main mediators of targeted cellular cytotoxicity, can be made by chemical crosslinking, by fusing hybridoma cells and by molecular genetic approaches. BsAbs bind to target cells via one V region and trigger molecules such as T-cell receptors (TCRs) or FcR for IgG (Fc gamma R) on cytotoxic cells via their other V region. This linking of triggering structures to target cells induces target cell lysis and provides important clues to the signals used to elicit the lytic process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676265     DOI: 10.1016/0167-5699(91)90156-N

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  5 in total

1.  Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes.

Authors:  E X Deramoudt; C Gilard; N Lepine; J M Alonso; J L Romet-Lemonne
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro.

Authors:  A Fernandez-Sesma; J L Schulman; T M Moran
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).

Authors:  I A Haagen; R van de Griend; M Clark; A Geerars; B Bast; B de Gast
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

4.  Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

Authors:  M R Shalaby; H M Shepard; L Presta; M L Rodrigues; P C Beverley; M Feldmann; P Carter
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

5.  Expression of tumor-associated glycoantigen, sialyl Lewis(a), in human head and neck squamous cell carcinoma and its application to tumor immunotherapy.

Authors:  K Makino; T Ogata; H Miyake; S Habu; T Nishimura
Journal:  Jpn J Cancer Res       Date:  1994-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.